Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Osivax logo — Pioneering A New Class of Universal Vaccines

Osivax

Pioneering A New Class of Universal Vaccines

Founded 2017 France France 53 employees Grant Total: $53.30M Biotechnology, Health Care

General Information

Company Name Osivax
Founded Year 2017
Location France France +2
Founders / Decision Makers
Team member Team member
Employees 53
Industries Biotechnology, Health Care
Funding Stage Grant
Social

Get notified when Osivax moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Osivax

Osivax is a clinical-stage biopharmaceutical company founded in 2017, with its headquarters in France. The company is pioneering a new class of universal vaccines utilizing the oligoDOM® nanoparticle platform technology. Their flagship product, OVX836, a broad-spectrum "universal" influenza candidate, is currently in Phase 2 clinical trials, with over 1200 subjects tested. The $1.50M grant investment received on 05 December 2023 was made by the National Institute of Allergy and Infectious Diseases. Osivax aims to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in a single shot. The company intends to extend its reach to other infectious disease indications through collaborations worldwide.

Taxonomy: immunology, vaccine, infectious diseases, pan-respiratory virus, cellular immune response, CD8 T-cell, immuno-oncology, nanoparticle platform technology, clinical-stage biopharmaceutical company, universal vaccines, ovx836, oligODOM, sarbocovirus, clinical trials

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 05 Dec 2023
Grant •••••• 1
Investor
28 Mar 2023
Grant •••••• 1
Investor
23 Jun 2022
Series B •••••• 2
Investor Investor
08 Jul 2020
Grant •••••• 2
Investor Investor
08 Jul 2020

View All 7 Funding Rounds

Osivax Alternatives & Competitors

Osivax vs
Calder Biosciences Inc.
Calder Biosciences Inc. United States

Improving & Saving Lives with the second generation of subunit vaccines to protect against life-thre...

Seed
8 employees
Biopharma, Biotechnology
Compare Osivax vs Calder Biosciences Inc.
Osivax vs
Vivaldi Biosciences
Vivaldi Biosciences United States

Developing nasal-spray, self-adjuvanting vaccines: DeltaFLU universal flu vaccine, and Delta-19 univ...

Series Unknown
11 employees
Biotechnology
Compare Osivax vs Vivaldi Biosciences
Osivax vs
Codagenix Inc.
Codagenix Inc. United States

Design Platform for Vaccine & Oncolytic Virus development ~ COVID, Flu, RSV, Dengue, YF / Breast Can...

Grant
19 employees
Biotechnology
Compare Osivax vs Codagenix Inc.

FAQ About Osivax

Pioneering A New Class of Universal Vaccines
Osivax was founded in 2017.
Osivax is headquartered in France.
Osivax operates in the following industries: Biotechnology, Health Care.
Osivax has approximately 53 employees.
Osivax has completed 7 funding rounds, raising a total of $53.30M. The latest funding stage is Grant.
Top alternatives and competitors to Osivax include Calder Biosciences Inc., Vivaldi Biosciences, Codagenix Inc., Ansun Biopharma, Inc., Mucosis. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Osivax and Calder Biosciences Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Osivax and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy